Acerola for Health & Longevity - Quick Reference Sheet

Acerola for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Acerola is a fruit unusually rich in vitamin C, and nearly all its effects follow from that. Where vitamin C status is low, it raises it efficiently: shorter colds, better iron absorption from plant foods, a small drop in blood pressure, improved artery-lining function. Where status is full, extra intake is largely excreted. Trade-offs are dose-dependent, not fruit-specific. (Full Review)

Protocol

Standard supplement protocol
500–1500 mg/day extract
Standardized to 17% or 25% ascorbic acid, delivering roughly 85–375 mg vitamin C, split across meals
Whole-fruit protocol
5–15 g powder or 100–300 g pulp daily
Food-first approach using unstandardized fruit powder or frozen pulp; comparable vitamin C dose plus the full polyphenol fraction
Best time of day
Divided doses with meals, morning and midday
A dose alongside the largest plant-iron meal maximises the absorption benefit; late-evening acidic doses can provoke reflux
Time to effect
Vitamin C status
1–2 weeks
Plasma vitamin C reaches a new steady state
Cold duration
Continuous intake
Cold-duration effects require continuous intake before exposure
Skin endpoints
84 days
The skin endpoints under study use 84-day protocols

Benefits

Contraindications
  • Latex allergy with documented prohevein sensitization, or prior reaction to acerola-containing products
  • Hereditary hemochromatosis or transfusional iron overload (ferritin >300 ng/mL in men or >200 ng/mL in women with transferrin saturation >45%)
  • Recurrent calcium oxalate nephrolithiasis (kidney stones), or 24-hour urinary oxalate >45 mg, unless intake stays at food levels
  • Chronic kidney disease stage 4 or 5 (filtration rate below 30 mL/min/1.73 m²), or dialysis
  • Primary hyperoxaluria of any type
  • Glucose-6-phosphate dehydrogenase deficiency, for gram-level extract doses
Key Interactions
  • Warfarin (caution; possible reduced anticoagulation)
  • Deferoxamine and other iron chelators (caution; cardiotoxicity)
  • Aluminum-containing antacids (aluminum hydroxide, magaldrate, sucralfate; caution; increased aluminum absorption)
  • Chemotherapy and radiotherapy (bortezomib, doxorubicin, cisplatin; caution; theoretical antioxidant interference)
  • Oral iron and iron-fortified foods (additive; increased absorption)
  • Other vitamin C sources (ascorbic acid tablets, camu-camu, rose hip, multivitamins, effervescent "immune" powders; additive; dose stacking)
  • Aspirin and other NSAIDs (nonsteroidal anti-inflammatory drugs; monitor)
  • Vitamin E and other antioxidant supplements (additive; potential blunting of training adaptation)

Risk & Side Effects

  • High: Gastrointestinal upset at high doses; increased oxalate excretion and kidney stone risk
  • Medium: Blunting of exercise training adaptations; interference with common laboratory and home tests
  • Low: Latex-cross-reactive allergic reaction; aggravation of iron overload in susceptible people; dental erosion from acidic preparations; higher age-related cataract rate with vitamin C supplements
  • Speculative: Rebound scurvy after abrupt withdrawal; hemolysis in glucose-6-phosphate dehydrogenase deficiency

Monitoring

Marker Target Why
Plasma vitamin C 50–70 µmol/L Establishes headroom and confirms the dose worked
Ferritin 30–100 ng/mL Detects the iron-loading state in which enhanced absorption is a harm
Transferrin saturation 20–35% Confirms or excludes iron overload before regular use
24-hour urinary oxalate <30 mg/24 h Directly measures the pathway by which vitamin C raises stone risk
Estimated glomerular filtration rate >90 mL/min/1.73 m² Kidney filtration governs oxalate clearance and dose tolerance
High-sensitivity C-reactive protein <1.0 mg/L Tracks the low-grade inflammation acerola is claimed to lower
ALT and AST ALT <25 U/L (men), <20 U/L (women) Reference point for the liver enzyme changes seen in the acerola athlete study
Fasting glucose 75–90 mg/dL Baseline for the disputed post-meal glucose effect
Serum uric acid 3.5–5.5 mg/dL Captures the small urate-lowering effect and monitors gout-prone individuals

Cadence: Baseline, then plasma vitamin C and any abnormal baseline rechecked at 8–12 weeks, then every 6–12 months while intake continues; for gram-level extract use, urinary oxalate and kidney function repeated annually.

Qualitative Assessment

  • Frequency and duration of upper respiratory infections across a full season
  • Gum bleeding when brushing or flossing
  • Skin appearance and wound healing time
  • Perceived recovery quality between hard training sessions
  • Digestive tolerance (loose stools or cramping)
  • Energy and exercise tolerance